SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Pacira Biosciences, Inc. - PCRX ...

Pacira BioSciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX ...

Pacira BioSciences, Inc. Is Being Sued For Securities Law Violations And Impacted Shareholders Are Urged To Contact The Schall Law Firm ...

NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX).Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pacira-biosciences-inc-loss-submission-form/?id=123062&from=4CLASS PERIOD: Augus ...

Please check back later to see all of our exciting changes. ...

NEW ORLEANS, Jan. 15, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company’s securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey. Get Help ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Pacira To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Pacira between August 2, 2023 and August 8, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Jan. 15, 2025 /PRNewswire/ -- ...

NEW YORK, Jan. 15, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024. A lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 14, 2025.So what: If you purchased Pacira securities during the Class Period, you may be entitled to compensation without ...

Class Action Lawsuit Against Pacira BioSciences - A class action lawsuit has been filed on behalf of individuals and entities that purchased or acquired Pacira BioSciences securities between August 2, 2023, and August 8, 2024 [1] - Pacira BioSciences is a pharmaceutical company focused on non-opioid pain management and regenerative health solutions [1] Allegations of Misrepresentation - The lawsuit alleges that Pacira BioSciences failed to disclose the lack of sufficient patent protection for its key product, Exparel [2] - Exparel, a bupivacaine liposome injectable suspension, accounts for approximately 80% of Pacira's revenue [3] - The company allegedly created a false impression that it had strong patent protections for Exparel, despite knowing that the '495 patent was not as protective as claimed [2] - On June 6, 2023, a New Jersey District Court ruled against Pacira in a patent infringement case against eVenus Pharmaceuticals related to Exparel [2] Impact on Stock Price - When Pacira announced the loss of the second lawsuit against eVenus on August 9, 2024, its stock price dropped from $22.36 per share to $11.70 per share, a decline of over 47% in a single day [3] Legal Proceedings and Shareholder Participation - Shareholders who wish to serve as lead plaintiff in the class action must submit their application to the court by March 14, 2025 [4] - Shareholders can choose to remain absent class members and still be eligible for recovery without participating in the case [4] - Robbins LLP, the law firm handling the case, operates on a contingency fee basis, meaning shareholders pay no fees or expenses [5]

Lawsuit Allegations - A shareholder class action lawsuit has been filed against Pacira BioSciences, Inc alleging that the company created a false impression regarding the sufficiency of patent protections on Exparel, impacting its marketing, production, and sales [1] - The lawsuit claims that Pacira was aware that the '495 patent was not as protective as publicly stated by the company [1] Legal Action Details - Shareholders who purchased Pacira shares between August 2, 2023, and August 8, 2024, and suffered significant losses are encouraged to contact Corey D Holzer, Esq for legal rights discussion [2] - The deadline to request the court to be appointed lead plaintiff in the case is March 14, 2025 [3] Law Firm Information - Holzer & Holzer, LLC, a top-rated securities litigation law firm, specializes in representing shareholders and investors in litigation, including class action and derivative cases [3] - Since its founding in 2000, the firm has recovered hundreds of millions of dollars for shareholders affected by fraud and corporate misconduct [3]